ESMO Live Update | Dr. Girard Analyzes PAPILLON: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion Mutant Advanced NSCLC

ESMO Live Update | Dr. Girard Analyzes PAPILLON: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion Mutant Advanced NSCLC

2023.11.28
Based on the results of the PAPILLON trial, presented at the 2023 ESMO Congress, a dual-specificity EGFR/MET monoclonal antibody has the potential to become a standard of care for EGFR exon 20 insertion mutant advanced or metastatic non-small cell lung cancer (NSCLC), although toxicity management must be approached with caution (Abstract LBA5). Dr. Nicolas Girard, the lead author of the study and a researcher at the Curie-Montsouris Thoracic Institute, discussed the implications of these findings for clinical practice in an interview with Oncology Insight conducted during the conference.
ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO

ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO

2023.11.27
The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from June 2 to June 6, 2023. Oncology Insight delves into the forefront of the conference, inviting researchers to share the most prominent Chinese research at ASCO, witnessing the advancement of China's anti-tumor efforts on the international stage. Professor Wu Yilong from the People's Hospital of Guangdong Province presented the results of the Phase III EVEREST study at ASCO 2023 in the form of an oral presentation. This article provides specific details of the EVEREST study and invites Professor Wu Yilong to provide an interpretation.
ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types

ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types

2023.11.27
TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this antigen has garnered significant attention. At the 2023 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20th to 24th, an innovative TROP2-ADC called SKB264 (MK-2870), jointly developed by CoromboTech and Merck, was presented in an oral report from a phase I/II basket trial for the treatment of advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) (Abstract number: 380MO). The study results confirm that SKB264 exhibits manageable safety and significant anti-tumor activity in HR+/HER2- metastatic breast cancer patients. Professor Yongmei Yin presented the research and its key findings at the conference.
ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients

ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients

2023.11.27
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain, from October 20th to 24th. Professor Tao Zhang and Professor Kaixiong Tao  from Tongji Medical College of Huazhong University of Science and Technology and their team conducted a randomized Phase III trial, the UNION study (Abstract Number: LBA25), entitled "Neoadjuvant Short-Course Radiotherapy Followed by Cetuximab in Combination with CAPOX vs. Long-Course Sequential Chemotherapy in the Treatment of Locally Advanced Rectal Cancer." The study was selected for presentation as a proffered paper at the ESMO conference. "Oncology Frontier" interviewed Professor Tao Zhang and Professor Kaixiong Tao , and they interpreted the UNION study from both internal medicine and surgery perspectives, sharing their insights and thoughts on perioperative treatment for rectal cancer. This issue compiles the relevant content for readers.
ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line

ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line

2023.11.27
The combination of immune checkpoint inhibitors and anti-angiogenic therapy has become a first-line treatment option for advanced renal cell carcinoma (aRCC), with previous studies including patients of all IMDC risk levels. During a dedicated session on urological oncology at the 2023 ESMO Congress, Professor Sheng Xinan from Peking University Cancer Hospital, on behalf of a clinical research team, presented the results of the first Phase 3 study focusing on immune combination therapy for high-risk IMDC patients with advanced kidney cancer, making it the first domestic Phase 3 study of first-line immune combination therapy for advanced kidney cancer. The positive results offer a new first-line treatment option for patients with advanced kidney cancer.
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

2023.11.27
Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought about a breakthrough in the survival of these late-stage patients. However, some recurrent metastatic patients may develop endocrine resistance, reducing the efficacy of treatment. The European Society for Medical Oncology (ESMO) 2023 Annual Congress, held in Madrid, Spain, on October 20, 2023, featured Professor Xiaojia Wang's poster presentation on the combination of anlotinib and fulvestrant (452P), providing new hope for these patients. Oncology Frontier invited Professor Xiaojia Wang from Zhejiang Cancer Hospital to share insights.